[Fullevir: in vitro and in vivo antiherpetic activity].
The antiherpetic properties of a fullerene derivative with aminocaproic acid (manufactured by Intelfarm Co. as Fullevir) were studied in in vitro (in sensitive cell cultures) and in vivo (on a murine model of experimental herpetic encephalitis) experiments. Fullevir was found to protect tissue culture cells from the cytodestructive action of herpes simplex virus type 1. It was estimated that ED50 = 5.3 microg/ml and ED90 = 29.1 microg/ml. The agent was most effective when it was administered before and 30 minutes after cell culture infection. The in vivo study established that Fullevir showed a significant protective effect in experimental herpetic encephalitis. The protection rates were 29.8% and 41.0% with the total doses of Fullevir of 500 mg/kg (p < 0.007) and 1000 mg/kg (p < 0.004), respectively. Thus, the in vitro and in vivo studies demonstrated the antiherpetic effect of a fullerene-aminocaproic acid complex (1-hydrofullereneaminocaproic acid, sodium salt) having the trade name Fullevir.